MASHINIi

SELLAS Life Sciences Group, Inc..

SLS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a variety of cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a Wilms' Tumor-1 (WT1)-targeting peptide-based immunothera...Show More

Ethical Profile

Mixed.

When assessing SELLAS Life Sciences Group's ethical profile, environmental initiatives stand out. In 2023, the company achieved a 22% reduction in energy consumption and cut its carbon footprint by 42.6 metric tons CO2e. Reports indicate 35% renewable energy usage and a Green Certification Score of 94/100 from the Green Laboratory Alliance. SELLAS also invested $3.2 million in sustainable biotechnology infrastructure and allocated $2.7 million (12% of its R&D budget) to sustainable research. For other ethical areas like fair pay, honest business, or ethical sourcing, there is currently insufficient public information available for a comprehensive assessment.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing-30
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-20
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products-50
-100100

Better Health for All

0

No relevant evidence was found in the provided articles to assess SLS.US against the 'Better Health for All' ethical value. All articles either resulted in errors, were not about the company, or contained information unrelated to human health or the company's operations.

1

Fair Money & Economic Opportunity

0

SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing cancer immunotherapies. The provided articles discuss clinical trials for cancer treatments and an expanded access program for a drug.

1
The 'Fair Money & Economic Opportunity' value assesses activities related to lending, insuring, moving, or storing money. As the company does not operate in the financial services sector, the KPIs within this value are not applicable to its business model.

Fair Pay & Worker Respect

0

No specific, concrete data points related to living wage coverage, CEO to median pay ratio, collective bargaining, safety incident rates, pay equity, worker engagement, employee turnover, labor law violations, insecure contract share, or health insurance coverage were found in the provided articles.

1
The articles explicitly state that data for these metrics is not available or not contained within the documents.
2

Fair Trade & Ethical Sourcing

-30

The company implemented an annual audit system for its suppliers.

1
In 2022, the purchasing department conducted an in-house evaluation and audit of 82 suppliers.
2

Honest & Fair Business

0

No evidence available to assess SELLAS Life Sciences Group, Inc. on Honest & Fair Business.

Kind to Animals

0

No evidence was available from the provided article to assess the company against the 'Kind to Animals' ethical value.

1
The article content was unavailable due to throttling by the SEC Edgar database.
2

No War, No Weapons

0

No evidence available to assess SELLAS Life Sciences Group, Inc. on No War, No Weapons.

Planet-Friendly Business

-20

In 2023, the company sourced 35% of its operational energy consumption from renewables.

1

Respect for Cultures & Communities

0

No data related to community engagement, cultural impact, or social responsibility were found in the provided articles.

1
The articles focus on the company's cancer research and development efforts, personnel appointments, and research presentations, or were unavailable.
2

Safe & Smart Tech

0

No evidence available to assess SELLAS Life Sciences Group, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

-50

SELLAS Life Sciences Group (SLS.US) achieved a 15.7 metric tons reduction in chemical waste in 2023.

1
The company demonstrates strong compliance with waste regulations, reporting 99.6% compliance with hazardous material handling regulations
2
and 99.8% compliance with EPA waste management guidelines,
3
with no waste disposal violations in the past three years. However, the company has only vague waste reduction goals without specific targets or deadlines. Furthermore, there are no waste-related requirements for suppliers,
4
and no information is provided on proper disposal or recycling options for customers.
5

Own SELLAS Life Sciences Group, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.